Cellexus Limited Appoints Dunn Labortechnik GmbH as Distributor in Germany
News Apr 28, 2010
This is part of a continued geographical expansion as the Company continues to grow.
Mr Paul Stubbing, Cellexus Limited Chief Operating Officer, said in a statement, "We are very pleased to have entered into a distribution agreement with Dunn Labortechnik, an organisation which has an excellent reputation in the German market and provides us with first class links to customers in Germany, which represents a significant market opportunity for Cellexus. We see this agreement as a great step forward for us as we continue to expand and very much look forward to working with the experienced team at Dunn Labortechnik to expand sales of the Cellexus products in Germany”.
Mrs Hannelore Dunn, Managing Director of Dunn Labortechnik, added: "We are very pleased to be working with Cellexus Limited in the sales of the Cellexus single use, disposable bioreactor systems in Germany and Austria." Mrs Dunn commented: “Cellexus is a reputable manufacturer with high quality products which ideally compliment our existing product range”.”
The Cellexus CellMaker systems apply single-use, disposable cell culture bioreactor bags with highly efficient methods to mix and oxygenate. Whilst other systems require shakers, rockers, rollers or large environmental chambers, the CellMaker systems employ a novel airlift technology which is simple, scalable, inexpensive to use and proven to out-perform cell culture in flasks. The CellexusBags, which are the unique single-use, disposable cell culture bags in which cells are grown in the CellMaker Regular system, enable fast set-up times and eliminate cleaning requirements. The CellMaker Regular very efficiently aerates the CellexusBag with controlled air flow providing oxygen for cell growth and gentle and effective mixing to maintain cells in suspension. Pressure control enhances oxygen availability to cells as well as decreases foaming and temperature control enables production of high yields of soluble protein under optimal conditions.
Cell Technology Used to Treat Osteochondral Knee DefectNews
Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE